Regel Therapeutics

Executive Summary

Regel Therapeutics is a preclinical-stage biotechnology company pioneering a novel Targeted EpiEditing platform that modulates gene expression without altering the DNA sequence. Founded in 2021 and headquartered in Cambridge, MA, the company aims to develop permanent cures for severe genetic diseases, with an initial focus on neurological disorders. The EpiEditing approach offers a potentially safer and more reversible alternative to traditional gene editing, as it does not involve double-strand breaks or permanent DNA modifications. Regel's lead programs are advancing toward the clinic, and the company is building a robust pipeline targeting conditions with high unmet need. Despite being at an early stage, Regel's proprietary technology positions it in the rapidly growing field of epigenome editing, attracting interest from investors and potential partners. The company's near-term prospects hinge on successful completion of IND-enabling studies and subsequent clinical trial initiation. Key upcoming catalysts include the release of preclinical efficacy and safety data, which could validate the platform in animal models of neurological disease. Additionally, Regel may seek strategic collaborations with larger biopharma to advance its programs or secure additional funding to support its pipeline. While the platform is promising, the company faces typical preclinical risks including translational uncertainty and regulatory hurdles. Nonetheless, if successful, Regel's Targeted EpiEditing could become a transformative therapeutic modality for a range of genetic disorders.

Upcoming Catalysts (preview)

• Q4 2026IND-enabling study results for lead neurologic program70% success
• Q2 2026Presentation of preclinical data at major conference (e.g., ASGCT)80% success
• H2 2026Series B financing or strategic partnership60% success